Knowledge of how PD-L1 is regulated in tumor cells is also essential for tackling open questions in PLB, such as why progression-free response to PLB is largely limited to patients expressing high PD-L1, and whether tumor PD-L1 is merely a biomarker for differential response to PLB. Here, CD274 is linked to neoplasm.